.avif)
ALK Gene Test - Childhood Cancer Biomarker
This ALK gene test detects ALK rearrangements and mutations to identify cancers (for example certain non‑small cell lung cancers, anaplastic large‑cell lymphomas and neuroblastomas) that may respond to ALK‑targeted therapies. Knowing your ALK status helps guide more effective, potentially less toxic treatment choices and avoid therapies unlikely to work.
WT1 Gene Test - Childhood Cancer Biomarker
This WT1 gene test detects inherited or de novo mutations that increase risk of Wilms tumor and other WT1‑related kidney and gonadal disorders (e.g., Denys‑Drash, Frasier syndromes). Knowing your result enables targeted surveillance, earlier treatment, and informed family planning to reduce disease-related complications.
MYCN Amplification Test - Childhood Cancer Biomarker
The MYCN amplification test detects whether the MYCN oncogene is amplified in tumor tissue—a key marker used to identify high‑risk neuroblastoma. Knowing MYCN status helps clinicians choose timely, more aggressive treatment and closer monitoring to reduce the risk of disease progression and improve outcomes.
.svg)
.png)